Tenderwize
Back to tender search

Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jul 31, 2026 · 24 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)

70/100

Opportunity Score

PromisingMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

70 / 100

Complexity

40 / 100

Risk factors

No minimum volume; actual demand depends on prescription behavior and patient numbers.

Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2026
  • Supply of Nilotinib (ATC L01EA03) under a non-exclusive framework agreement.
  • Excludes Nilotinib dispersed in apple sauce unless patented.
Show full summary

Non-exclusive drug discount agreement for Nilotinib (ATC L01EA03) via an Open-House model. Contract ends 31.07.2026. Open to all qualified pharmaceutical entrepreneurs meeting German statutory requirements. No guaranteed volumes or exclusivity. Estimated value not published. Submission possible periodically until final deadline.

Risks

No minimum volume; actual demand depends on prescription behavior and patient numbers.

Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered medicinal products.
  • Legal seat within Germany, EU, or EEA (§9 Abs. 2 AMG).

Eligibility

  • No exclusion grounds under §§123, 124 GWB (submission of self-declaration).

Requirements may be incomplete.

Buyer

Name

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib

Single lot covering Nilotinib (excluding apple sauce dispersion unless patented). Open House model – any qualified pharmaceutical entrepreneur may join by submitting required documents. No negotiation or exclusivity.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jul 2025 - Jul 2026

Category

Pharmaceutical products

Deadline

Deadline Jul 31, 2026

Procurement Details

Publication date
29 May 2025
Notice type
Contract notice — standard
Languages
German

Reference metadata

Notice subtype
16
Notice version
1
Legal basis
32014L0024

Reference IDs

Tender ID
349678-2025

Documents (1)

Similar tenders